Ignite Creation Date:
2025-12-26 @ 1:19 PM
Ignite Modification Date:
2026-01-15 @ 12:51 PM
Study NCT ID:
NCT05068206
Status:
UNKNOWN
Last Update Posted:
2021-10-20
First Post:
2021-09-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-10-08
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-06
Completion Date Type:
ESTIMATED
First Submit Date:
2021-09-24
First Submit QC Date:
None
Study First Post Date:
2021-10-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-10-18
Last Update Post Date:
2021-10-20
Last Update Post Date Type:
ACTUAL